Travel health could be improved with a recent discovery that has identified a potential new malaria prevention therapy.
Scientists made the breakthrough while carrying out tests at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University in Montreal.
They identified a crystal-like substance hemozoin, which is instrumental in the progression of malaria that causes it to progress into serious inflammation and fever.
The study's first-author Dr Marina Tiemi Shio, of the RI-MUHC, commented: "Our results describe the mechanism by which the hemozoin activates the immune system, resulting in the production of inflammation mediators and in the high fever that we witness in malaria patients."
Dr Martin Olivier, who led the study, added: "These results prove the primary role hemozoin plays in the development of malaria, and designates it as a favoured choice for future innovative treatments."
Malaria is prevalent in sub-tropical parts of the world and causes the death of between one and three million people in the world every year.